Live Breaking News & Updates on Preclinical challenge study

Stay informed with the latest breaking news from Preclinical challenge study on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Preclinical challenge study and stay connected to the pulse of your community

CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020

CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
- COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission
- Pivotal Phase 2b/3 in Europe and Latin America fully recruited with over 40,000 participants. Interim analysis for vaccine efficacy expected in Q2 2021
- Phase 2a trial in Peru and Panama amended for addition of secondary endpoint for vaccine efficacy in total population with a focus on participants over the age of 60
- CVnCoV demonstrates, in preclinical challenge study, full protection from infections with Variant of Concern B.1.351 (South Africa variant)

Germany , United-states , United-kingdom , Belgium , Brazil , Boston , Massachusetts , South-africa , Austria , Peru , Panama , Switzerland

Investegate |CureVac Announcements | CureVac: CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020

DGAP-News: CureVac
/ Key word(s): Quarter Results/Annual Results
CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
15.04.2021 / 13:30
CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
-
COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission
- Pivotal Phase 2b/3 in Europe and Latin America fully recruited with over 40,000 participants. Interim analysis for vaccine efficacy expected in Q2 2021
- Phase 2a trial in Peru and Panama amended for addition of secondary endpoint for vaccine efficacy in total population with a focus on participants over the age of 60

Germany , United-states , United-kingdom , Belgium , Brazil , Boston , Massachusetts , South-africa , Austria , Peru , Panama , Switzerland